Desbridamento
Titular da Autorização de Introdução no Mercado
Smith & Nephew, Lda. Parque Tejo - Bloco C, Estr. Nac. 10 ao Km 131, 2625-445 Forte da Casa, Portugal.
Tel: +351 214 460 650
Fax: +351 214 460 679
regulatory.pt@smith-nephew.com
Número de autorização de introdução no mercado: 8415802
Data da primeira autorização de introdução no mercado: 7 de Novembro de 1974.
Data da última revisão (parcial) do texto: 24/07/2006.
- Informações Clínicas
- Indicações Terapêuticas
- Resumo das características do medicamento ULCERASE
Queimaduras superficiais (1º e 2º grau), Úlceras varicosas e de decúbito e Feridas superficiais da pele.
Ulcerase pomada não foi testado em crianças, daí não se recomendar a sua utilização em crianças com idade inferior a 12 anos.
- Folheto Informativo ULCERASE
- Apresentação e códigos
| Código produto SN |
CNP | Descrição | Unidades Caixa |
Unidade mínima venda |
| 66425030 | 8415802 | ULCERASE | 1 u | 1 u |
Bibliografia
1. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746.
2. Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care. 2004;17:24-35.
3. Schultz GS, Mast BA. Molecular analysis of the environments of healing and chronic wounds: cytokines, proteases, and growth factors. Wounds. 1998;10(suppl F):1F-9F.
4. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007;127:514-525.
5. Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2005;28:461-471.
6. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen. 1999;7:433-441.
7. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 1996;4:411-420.
8. Ayello EA, Cuddigan JE. Debridement: controlling the necrotic/cellular burden. Adv Skin Wound Care. 2004;17:66-75. 9. Enoch S, Harding K. Wound bed preparation: the science behind the removal of barriers to healing. Wounds. 2003;15:213-229.
10. Steed DL. Debridement. Am J Surg. 2004;187:71S-74S.
11. Fowler E, van Rijswijk L. Using wound debridement to help achieve the goals of care. Ostomy Wound Manage. 1995;41:23S-35S.
12. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11:1-28.
13. Sibbald RG, Williamson D, Orsted HL, et al. Preparing the wound bed–debridement, bacterial balance, and moisture balance. Ostomy Wound Manage. 2000:46;14-35.
14. Hellgren L, Vincent J. Debridement: an essential step in wound healing. In: Westerhoff W, ed. Leg Ulcers: Diagnosis and Treatment. Amsterdam, Netherlands: Else¬vier Science; 1993:305.
15. Brem H, Lyder C. Protocol for the successful treatment of pressure ulcers. Am J Surg. 2004;188:9S-17S.
16. Robson MC, Cooper DM, Aslam R, et al. Guidelines for the treatment of venous ulcers. Wound Repair Regen. 2006;14:649-662.
17. Whitney J, Phillips L, Aslam R, et al. Guidelines for the treatment of pressure ulcers. Wound Repair Regen. 2006;14:663-679.
18. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006;14:680-692.
19. Mandl I. Collagenases and elastases. In: Nord FF, ed. Advances in Enzymology. New York, NY: Interscience Publishers, Inc.; 1961:163-264.
20. Boxer AM, Gottesman N, Bernstein H, Mandl I. Debridement of dermal ulcers and decubiti with collagenase. Geriatrics. 1969;24:75-86.
21. Lee LK, Ambrus JL. Collagenase therapy for decubitus ulcers. Geriatrics. 1975;30:91-98.
22. Altman MI, Goldstein L, Horowitz S. Collagenase: an adjunct to healing trophic ulcerations in the diabetic patient. J Am Podiatry Assoc. 1978;11-15.
23. Hansbrough JF, Achauer B, Dawson J, et al. Wound healing in partial-thickness burn wounds treated with collagenase ointment versus silver sulfadiazine cream. J Burn Care Rehabil. 1995;16:241-247.